On this page
An athlete under the World Anti-Doping Code can be sanctioned for BPC-157 whether the sample was collected at a meet or on a Tuesday in the off-season. A pharmacy question in the United States is a separate file: FDA approval, the 503A Bulks List, and the October 28, 2026 HHS draft. The sport ban is this page.
Update, October 28, 2026
I read the public-inspection PDF for Federal Register document 2026-22192 and the policy file it links. HHS filed it on October 28, 2026. It publishes October 30. HHS says it does not intend to take action against a state-licensed pharmacy, a federal facility, or a licensed physician who compounds BPC-157 when the conditions are met, including a prescription for a specific patient. FDA has not approved BPC-157. The 503A Bulks List is unchanged. The notice calls the policy a draft and says it is not binding.
If you compete under the World Anti-Doping Code, this filing does not help you. WADA class S0 still prohibits BPC-157 at all times. A pharmacy that sits inside the HHS draft can still leave an athlete with a sanction. The conditions, the six peptide names, and the NBC story are on is BPC-157 legal?.
The human studies, which are small and uncontrolled, are listed in BPC-157 human trials. The molecule it is sold beside is covered in BPC-157 vs TB-500. The research profile is BPC-157.
Where BPC-157 stands on October 15, 2026
| Item | Mark | What the document says | Source |
|---|---|---|---|
| WADA 2026 List | Mark Prohibited at all times | What the document saysNamed in S0. Every substance in S0 is a Specified Substance. In and out of competition. | SourceWADA 2026 List |
| USADA 2026 list | Mark Same class | What the document saysPremier Sports policy incorporates the WADA List and names BPC-157 in S0. | SourceUSADA |
| FDA approval | Mark None | What the document saysNo approved drug. No USP or NF monograph for the free base or the acetate. | SourceFDA PCAC briefing |
| 503A Bulks List | Mark Not listed | What the document saysNot in Category 1, 2, or 3 of the May 14, 2026 categories document. | SourceFDA 503A categories |
| Nominations | MarkWithdrawn | What the document saysFDA lists BPC-157 with substances previously in Category 2 whose nominations were withdrawn. A withdrawal does not place it on the Bulks List. | SourceFDA safety-risks page |
| PCAC, July 23, 2026 | MarkStaff proposed no | What the document saysFDA asked the committee to vote. Staff proposed that the free base and the acetate stay off the list. FDA has not posted minutes or a tally. | SourceFDA slides and questions |
| HHS draft, Oct 28, 2026 | MarkFiled | What the document saysDocument 2026-22192. Enforcement discretion for listed compounders. Not an approval. Bulks List unchanged. Sport ban unchanged. | SourceHHS public inspection |
| Canada | Mark Not authorized | What the document saysApril 9, 2026 advisory names BPC-157. May 7, 2026 Type I recall of powder, RA-82047. | SourceHealth Canada |
What WADA class S0 means
S0 is the class for a pharmacological substance that later sections of the List do not cover and that no government health authority has approved for human therapeutic use. The 2026 List, in force January 1, 2026, says this class is prohibited at all times. It then names examples, "including but not limited to BPC-157."
The same block says every prohibited substance in the class is a Specified Substance. Specified is a sanction category in the Code. It does not mean the substance is allowed out of competition. The header over S0 is "prohibited at all times (in- and out-of-competition)."
USADA's 2026 Premier Sports Prohibited List incorporates the current WADA List and repeats BPC-157 in the S0 examples, again prohibited at all times, again a Specified Substance. USADA's athlete page states the same prohibition and says BPC-157 is not approved for human clinical use by FDA or any other global health authority.
A therapeutic-use exemption is a separate application. USADA's page says a TUE for BPC-157 is unlikely because permitted alternatives exist, and that each application is still read on its own facts. The 2022 athlete advisory said there is no basis for a TUE because BPC-157 is not an approved therapeutic agent in any country.
Supplement labels and athlete sanctions
A tub can say "supplement" and still contain a prohibited substance. USADA's 2022 advisory said BPC-157 was being included in some wellness and anti-aging products, and that there appeared to be no legal basis for selling it as a drug, a food, or a dietary supplement.
A positive lab test is not the only way a case starts. On August 13, 2024, an independent arbitrator heard the case of speedskater Kamryn Lute. She declared use of a supplement containing BPC-157 that a medical provider had recommended. She never tested positive. The arbitrator imposed a one-year sanction. USADA's announcement says the default for a Specified Substance such as BPC-157 is two years, with a reduction when an athlete admits the violation without other evidence.
USADA's athlete page, updated after FDA's compounding briefing, says there is currently no legal basis to include BPC-157 in a compounded medication. That is USADA's reading of the briefing. The FDA documents themselves are below.
The 2026 FDA compounding record
FDA has not approved a drug containing BPC-157. The July 2026 briefing for the Pharmacy Compounding Advisory Committee says there is no USP or NF monograph for BPC-157 free base or BPC-157 acetate, and that the two are different bulk drug substances. Under section 503A, a bulk substance can be used in compounding if it has an applicable monograph, or is a component of an FDA-approved drug, or is on the 503A Bulks List. BPC-157 meets none of those three.
Read this next BPC-157 research profile
The categories document updated May 14, 2026 does not place BPC-157 in Category 1 (under evaluation), Category 2 (significant safety risks), or Category 3 (nominated without adequate support). Category 1 is the group for which FDA's interim policy generally does not intend to take action while an evaluation runs. BPC-157 is not in that group.
FDA's safety-risks page lists BPC-157 under "bulk drug substances nominated but withdrawn," substances previously in Category 2 whose nominators withdrew. The page says compounded drugs containing BPC-157 may pose a risk of immunogenicity for certain routes, and that FDA has no, or only limited, safety information for the proposed routes. The May 14 categories document uses April 22, 2026 as the withdrawal date for GHK-Cu, not for BPC-157, so this page does not assign BPC-157 that date.
A withdrawn nomination does not add a substance to the 503A Bulks List. The Bulks List is made by notice-and-comment rulemaking.
On July 23, 2026, FDA asked the committee to vote on two questions: should BPC-157 free base be placed on the list, and should BPC-157 acetate be placed on the list. The staff slides propose that neither be included. FDA has not posted the minutes. This page does not repeat a vote count from secondary reports.
The Washington Post reported on October 7, 2026 that the advisory committee recommended six of the seven peptides it reviewed and voted against emideltide, after FDA scientists urged the panel to vote no. The Post said FDA is not required to follow the panel, and that formal rulemaking had no clear date. The Unified Agenda entry for further amendments to the 503A Bulks List (RIN 0910-AI70) is still at the proposed-rule stage, with no Federal Register citation. We did not find a published proposed rule adding BPC-157 as of October 15, 2026.
The same Post story said officials were crafting a plan for temporary sale of some previously restricted peptides while rules were written. Two unnamed sources described the plan. HHS did not comment. The Post said the plan had not been announced and could still change, and that it was not clear which peptides it would cover. No order matching that description had been issued as of October 15, 2026. The October 28, 2026 filing is the later document, and it is summarized in the update.
Canada
Health Canada's April 9, 2026 advisory names BPC-157 among unauthorized injectable peptide drugs it has seized. The advisory says these products are illegal in Canada, have not been assessed for safety, efficacy, and quality, and that a "For Research Use Only" label does not make them legal. Authorized prescription drugs carry an eight-digit Drug Identification Number.
On May 7, 2026, Health Canada posted a Type I recall, RA-82047, of BPC-157 powder sold as an unauthorized active ingredient. The recall date is May 5, 2026. The depth of recall is compounding and community pharmacies.
We have not reviewed regulators outside the United States and Canada for this page. A later pass over the same FDA and Health Canada documents, dated October 23, 2026, is is BPC-157 legal. The WADA file stays here.
What would change this status
The WADA prohibition changes when WADA publishes a List that no longer covers BPC-157. The 2026 List is the one in force.
A final rule placing the free base or the acetate on the 503A Bulks List, an FDA approval, or a monograph would change the statutory compounding test. A committee recommendation does not do that. The October 28, 2026 HHS notice is a draft decision not to enforce, inside the conditions on the legal-status page. It leaves the Bulks List where it was.
In Canada, authorization would show up as a Drug Identification Number in the Drug Product Database. The April and May 2026 notices are still the public record.
Common questions
Is BPC-157 banned for athletes?
Yes. The 2026 WADA Prohibited List names BPC-157 in class S0 and prohibits it at all times, in and out of competition. USADA's 2026 Premier Sports list does the same.
Is BPC-157 FDA-approved?
No. FDA's July 2026 compounding briefing treats BPC-157 free base and BPC-157 acetate as unapproved bulk substances with no USP or NF monograph. We did not find an approved drug containing BPC-157 as of October 15, 2026.
Can a pharmacy compound BPC-157?
It is not on the 503A Bulks List, not in Category 1, and the nominations were withdrawn. FDA staff proposed on July 23, 2026 that it stay off the list. On October 28, 2026 HHS filed a draft that says it does not intend to take action when a state-licensed pharmacy, a federal facility, or a licensed physician compounds it under the conditions on the legal-status page. That draft is not a Bulks List entry. The WADA ban still applies to athletes.
Did removal from Category 2 make BPC-157 legal?
No. FDA lists it with substances previously in Category 2 whose nominations were withdrawn. That listing does not add it to the 503A Bulks List.
Did the July 2026 committee vote change the rule?
FDA has not posted minutes, and we did not find a proposed rule adding BPC-157. The Washington Post reported that the panel recommended six of seven peptides and that FDA does not have to follow the panel.
Is BPC-157 legal in Canada?
Health Canada has not authorized it. The April 9, 2026 advisory names it among seized unauthorized injectable peptides, and a May 2026 Type I recall covers BPC-157 powder sold as an active ingredient.
Sources
Methodology. Status checked October 15, 2026 against the WADA 2026 Prohibited List, USADA's 2026 Premier Sports Prohibited List and athlete pages, FDA's May 14, 2026 503A categories document, FDA's withdrawn-nomination safety page, the July 23-24, 2026 PCAC slides, questions, and briefing, the Unified Agenda entry RIN 0910-AI70, the Washington Post of October 7, 2026, and Health Canada's April 9 and May 7, 2026 notices.
Primary sources.
- WADA, 2026 Prohibited List: https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- USADA, Premier Sports Prohibited List 2026: https://www.usada.org/wp-content/uploads/USADA_PremierSports_ProhibitedList_Policy_2026_Digital.pdf
- USADA, BPC-157 athlete page: https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- USADA, key changes on the 2022 List: https://www.usada.org/athlete-advisory/key-changes-2022-prohibited-list/
- USADA, Kamryn Lute sanction: https://www.usada.org/sanction/independent-arbitrator-imposes-sanction-kamryn-lute/
- FDA, 503A categories, updated May 14, 2026: https://www.fda.gov/media/94155/download
- FDA, bulk substances that may present significant safety risks: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC slides, July 23-24, 2026: https://www.fda.gov/media/193773/download
- FDA PCAC questions: https://www.fda.gov/media/193711/download
- FDA PCAC briefing on BPC-157: https://www.fda.gov/media/193343/download
- Unified Agenda, RIN 0910-AI70: https://www.reginfo.gov/public/do/eAgendaViewRule?RIN=0910-AI70&pubId=202510
- Washington Post, October 7, 2026: https://www.washingtonpost.com/health/2026/10/07/trump-administration-paving-way-temporary-sale-some-unapproved-peptides/
- HHS, Federal Register public inspection, document 2026-22192, filed October 28, 2026: https://public-inspection.federalregister.gov/2026-22192.pdf
- HHS enforcement discretion policy PDF: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- NBC News, Berkeley Lovelace Jr., October 28, 2026: https://www.nbcnews.com/health/health-news/rfk-jr-takes-shortcut-make-peptides-widely-available-rcna606133
- Health Canada advisory, April 9, 2026: https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm
- Health Canada recall RA-82047, May 7, 2026: https://recalls-rappels.canada.ca/en/alert-recall/ghk-cu-bpc-157-powder-unauthorized-active-pharmaceutical-ingredients
Left out. A numeric committee tally appears in secondary reports. It is not in the FDA minutes or slides we reviewed, so it is not repeated here. An April 22, 2026 removal date is in the categories document for GHK-Cu, not for BPC-157.
Changes. October 15, 2026: first published. October 28, 2026: added the HHS draft. The WADA prohibition is unchanged.
